The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
Open accessAbstract
Dysregulation of metabolism is a common phenomenon in cancer cells. The NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) function at a crossroads of cellular metabolism in lipid synthesis, cellular defense against oxidative stress, oxidative respiration, and oxygen-sensing signal transduction. We review the normal functions of the encoded enzymes, frequent mutations of IDH1 and IDH2 recently found in human cancers, and possible roles for the mutated enzymes in human disease. IDH1 and IDH2 mutations occur frequently in some types of World Health Organization grades 2-4 gliomas and in acute myeloid leukemias with normal karyotype. IDH1 and IDH2 mutations are remarkably specific to codons that encode conserved functionally important arginines in the active site of each enzyme. To date, all IDH1 mutations have been identified at the Arg132 codon. Mutations in IDH2 have been identified at the Arg140 codon, as well as at Arg172, which is aligned with IDH1 Arg132. IDH1 and IDH2 mutations are usually heterozygous in cancer, and they appear to confer a neomorphic enzyme activity for the enzymes to catalyze the production of D-2-hydroxyglutarate. Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a renewed interest in the area of cancer metabolism with metabolic reprogramming coined as a hallmark of cancer based on the discovery of mutations and alterations in IDH1 and IDH2 along with succinate dehydrogenase (SDH), fumarate hydratase (FH), and pyruvate kinase M2 (PKM2) [41, 42].”
From Modeling APC mutagenesis and familial adenomatous polyposis using human iPS cells (2018) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Research works printed but not linked: 7
- 2008, 154, 1107
- 2004, 86, 501
- 2001, 83, 1057
- 2008, 90, 1316
- 2009, Cancer Science, 15, 6002
- 2009, Human mutation, 31, 279
- 2009, New England Journal of Medicine, 360, 2248, 10.1056/NEJMc090593 · DOI
Cited by
Sorted by citations
Items 501–567 of 567
An Overview of Carbonic Anhydrase-Related Neoplasms
Takáčová, M., & Pastoreková, S. (2021) · Progress in drug research · doi:10.1007/978-3-030-79511-5_7
Molecular Regulation of Vascular Abnormalization and Its Role in Glioma
Zhang, L. (2015) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Prognostic significance of GLUT-1 and p-Src expression in Mucoepidermoid carcinoma
Salama, N., & Amin, L. E. (2022) · Egyptian Dental Journal /Egyptian Dental Journal · doi:10.21608/edj.2021.97874.1800
“Several glycolytic genes, including pyruvate kinase isozyme M2 (PKM2), lactate dehydrogenase A (LDHA), hexokinase 2 (HK2), and glucose transporter (GLUT), are highly expressed in malignant tumors and have been associated with tumor aggressiveness [21, 22].”
BackgroundTonini, G., Iuliani, M., Ribelli, G., Simonetti, S., & Pantano, F. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_41
Glioblastomas - Study Using Molecular Markers
Bon, E. I., & Vihanga, B. T. (2022) · Journal of Diseases Disorders & Treatments · doi:10.47363/jddt/2022(2)106
Targeted Treatments for Hematological Cancers
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch7
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G. A., & Sosman, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_55
El‐Deiry, W. S., & van den Heuvel, P. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717957017.793462921
IDH1 (Isocitrate Dehydrogenase 1)
Bristot, I. J., França, F. S., & Klamt, F. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101639-1
Choate, K. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726744181.793558674
Wang, X. W. (2012) · theses.fr (ABES) · doi:10.70675/ff2a5a94z272fz449fz844bzd0227e4143b7
“isocitrate to the intermediate oxalosuccinate, reducing NAD(P)+ to NAD(P)H, followed by decarboxylation of oxalosuccinate to form α-ketoglutarate (69) (Figure 6).”
BackgroundTargeting ROS Induced Epigenetic Reprograming in Cancer Stem Cells
Koul, H. K., Saikolappan, S., Kumar, B., & Koul, S. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_69-1
Ο ρόλος των μαστοκυττάρων στα μυελοδυσπλαστικά σύνδρομα
Καρράς, Γ. (2022) · doi:10.12681/eadd/52837
Targeting ROS-Induced Epigenetic Reprograming in Cancer Stem Cells
Koul, H. K., Saikolappan, S., Kumar, B., & Koul, S. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_69
Blau, O., Schwarzer, R., & Blau, I. W. (2016) · EMJ Oncology · doi:10.33590/emjoncol/10311896
Pre-leukemic Cell Detection and Leukemic Transformation of a Normal Marrow Cell: A Mini review
Chhetri, B. R., Thapa, R., Shrestha, D., Paudel, A., Adhikari, S., & Gautam, A. (2022) · International Journal of Applied Sciences and Biotechnology · doi:10.3126/ijasbt.v10i4.49499
“IDH 1 and 2 gene mutations disrupts the lipid synthesis, lowers the defense against oxidative stress, thus leading to error in oxygen-sensing transduction, can impair hematopoietic differentiation (Reitman and Yan, 2010).”
BackgroundMolecular Typing of fumC, icd, and mdh Genes in Serratia Marcescens
Hamzah, A. S. (2023) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_93_23
“[18] ] These genes encode for enzymes that are considered crucial in the oxidative pathways and release energy that is used by the cell to catalyze gene expression of virulence factors to invade tissue via the mechanism of pathogenicity as well as other biological activities.”
BackgroundMutated isocitrate dehydrogenase and therapeutic modalities
Chen, K. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/6/20230245
The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132HPreprint
Kahlert, U. D., Mehjardi, N., Sanin, A. Y., Picard, D. J., Westhoff, P., Nickel, A., Uhlmann, C., Shi, W., Steiger, H.-J., Remke, M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3216060/v1
Guo, L., Liu, X., Zhang, J., Liu, Z., Zhang, B., Sun, Y., Cui, D., & Liu, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13802
“Of note, isocitrate dehydrogenase 2 (IDH2) is a catalytic enzyme that oxidatively decarboxylates isocitrate to α-ketoglutarate (α-KG) [14].”
BackgroundGliomas Difusos do Adulto: Prevalência da Mutação IDH1 em um Hospital Universitário
Rizzo, V. B., Ramos, M. A., de Castro, E. M., dos Santos-Neto, P. H., & Mehanna, S. H. (2025) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2024v70n4.4936
“Las mutaciones en la enzima isocitrato deshidrogenasa (IDH) identificadas en algunos tumores gliales marcan el inicio de la carcinogénesis, aumentando la funcionalidad de las enzimas metabólicas IDH1 e IDH2.”
InfluentialMethods for Increasing Coenzyme II
Xie, Y., & Sheng, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-9877-3_11
de Mayo, T., García‐Bloj, B., Godoy, J. A., Chávez, F. S., Retamal, I. N., Gómez‐Valenzuela, F., Silva, I., Muñoz‐Medel, M., Sánchez, C., Pinto, F., et al. (2025) · BJR|case reports · doi:10.1093/bjrcr/uaaf019
Brain cancer: Current and new drug delivery systems
Naik, G. A. R. R., Roy, A. A., Dhas, N. L., Mutalik, S., Tıwarı, R., Tiwari, G., & Kudarha, R. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29168-5.00021-0
Brain/CNS cancer: Advances in diagnostic research
Roy, A., Naik, G. A. R. R., Mutalik, S., Dhas, N. L., Tiwari, R., Tiwari, G., Patel, J. K., & Kudarha, R. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33849-6.00005-2
Extruded Spirulina and enzyme supplementation modulate hepatic proteome and metabolism in broilers
Spínola, M. P., Maslov, D. R., Rubić, I., Costa, M. M., Mrljak, V., Lordelo, M. M., de Almeida, A. M., & Prates, J. A. M. (2025) · Research in Veterinary Science · doi:10.1016/j.rvsc.2025.105824
Lysine- R 2HGylation identified as a post-translational modification in R 2HG-elevated cancersPreprint
Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680013
NAD+ as a Target for Cancer Treatment
Helman, T. J., & Braidy, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_269
Cai, C., Spinrad, M. W., Gattie, L. C., Wang, R., Afjal, M. A., Yang, J., Yadak, N., Shibata, D., Li, W., Bajwa, A., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103751
A Review of Recent Developments in Schiff Base Derivatives for Cancer Treatment
Ngu, C. P., Sahu, R., Shah, K., Paliwal, D., Sah, A. K., & Thakur, A. (2025) · Current Organic Chemistry · doi:10.2174/0113852728405259250924102913
Epigenome in gliomas: novel targets for therapy
Ashesh, A. M., Lari, M. Q., Chaurasia, Y., Kumar, A., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00006-6
Epigenetic modifications and therapies of gliomas: a precision medicine perspective
Gupta, P., Shukla, Y. K., Suryavanshi, A., Vandana, Kesavan, K., & Bharti, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00004-2
THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA
Demir, H., Özdemir, Ç., Baykara, M., Demirci, A., Beypınar, İ., Davarcı, S. E., Özdemir, C. Y., Çulha, Y., & Arıöz, D. T. (2026) · Kocatepe tıp dergisi. · doi:10.18229/kocatepetip.1576255
Kume, S., Gomyo, M., Kobayashi, K., Saito, K., Shimizu, S., Suzuki, K., Maruyama, K., Tsuchiya, K., Shiokawa, Y., Tanaka, Y., et al. (2026) · Research Connections · doi:10.1093/rescon/vmag015
Huber, S., Goessweiner, F., Walter, W., Summerer, I., Meggendorfer, M., Ordemann, R., Pohlkamp, C., Kneisel, N., Haferlach, C., Kern, W., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019387
Isocitrate dehydrogenase mutations as potential tumour agnostic targets
Macarulla, T. M., Tabatabai, G., Stacchiotti, S., & Bridgewater, J. A. (2026) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2025.12.002
“The IDH2 and IDH3 enzymes are lo - cated in the mitochondria, whereas the IDH1 enzyme is lo - cated in the cytosol and peroxisomes [ 4 ] .”
KIAA 0510, Ténascine R, et astrocytomes pilocytiques
Ayachi, I. E. (2010) · theses.fr (ABES) · doi:10.70675/0e9b78fcz07aaz49baz9438z0925e5029be4
Etude des réponses induites par l’erlotinib dans des cellules de lignées de glioblastome
Eimer, S. (2011) · theses.fr (ABES) · doi:10.70675/48cf26bbz6b1cz4672za2d5zc83a7ce5752a
Le rôle de GDF11 dans les leucémies aiguës myéloïdes
Siavellis, J. (2021) · theses.fr (ABES) · doi:10.70675/b953e730zc0bez4347za9e4z561daebbcc2d
Stage-specific changes in the Krebs cycle network regulate human erythroid differentiation
Romano, M. (2018) · theses.fr (ABES) · doi:10.70675/4312681cz0207z4923zb100z879f8a73681c
Characterization of cellular heterogeneity in Diffuse Low Grade Glioma
Augustus, M. (2020) · theses.fr (ABES) · doi:10.70675/037c23a4z44ddz4bb7z999ezb0c178c35170
2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation
Thamim, M., Dhabal, D., Balamurali, M. M., & Thirumoorthy, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1791517
“During catalysis, the domains undergo conformational changes, shifting from an open to a quasi-open to a closed state, with the closed conformation representing the catalytically active enzyme (25, 26).”
InfluentialRedox-modulation of regulated cell death: implications for synergistic anticancer therapies
Singh, P., Sridhar, S., Balasubramanian, D., Maigandan, D., Chandramoorthy, H. C. K., Ganesan, T. T., & Gandhirajan, R. K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05320-x
“…during nutrient deprivation or detachment-induced stress, the IDH1 (cytosolic) and IDH2 (mitochondrial) enzymes serve as pivotal “meta-bolic crossroads,” recycling NADP + into NADPH to defend against lipid peroxidation and support mitochondrial respiration (Shao et al. 2020; Reitman and Yan 2010).”
王, 家. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662262
Pharmacological strategies for glioblastoma: Current therapies, challenges, and emerging targets
Hoti, J., & Tomanelli, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105451 · Cited by 1
Sensory decline in aging and neurodegeneration: A mitochondrial perspective
Adeboye, O., Gonda, B. L., Gulati, N., Hu, K., Karp, A. R., McNally, D. C., Tsai, W., Zarate, J. G., Holmes, M., Johnson-Kleinpeter, L., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108322 · Cited by 1
“For example, loss of isocitrate dehydrogenase 2 (IDH2), which is an enzyme crucial for providing NADPH to major mitochondrial antioxidants [161], results in accelerated loss of spiral ganglion neurons and hair cells in the cochlea of male mice, and associated ARHL [162].”
Role of isocitrate dehydrogenase enzyme in brain cancer, with a focus on glioma
Alkhalaileh, L., Essam, Z. M., Ibrahim, M. A., & Al-khalayleh, M. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_96_2026
Ifham, A. (2026) · Biomedical Letters · doi:10.47262/bl/12.1.20260304
CSF3R/CD114: A predictor related to worse survival in gliomas
Bark, S. A., Buffon, V. A., Collaço, L. M., Giovanini, A. F., Bernardo, A., Cardoso, D., & Isolan, G. R. (2026) · BioSCIENCE · doi:10.55684/2026.84.en.e00017
Stupnikova, G. S., Popov, I. A., & Игоревич, П. С. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1890663
“…in IDH genes (IDH1, IDH2), which encode isocitrate dehydrogenase 1 and 2 - cytosolic and mitochondrial enzymes responsible for the oxidative decarboxylation of isocitrate to α -ketoglutarate ( α KG) (Boscoe et al., 2019; Reitman and Yan, 2010; Kipp et al., 2012; Dorovatovskaia et al., 2025).”
Mitochondrial Cristae as Separate Compartments: Linking Organization and Function
Panov, A. V., Nesterov, S. V., & Yaguzhinsky, L. S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080792
“…dehydrogenase 1 (ICDH1) carries out the reverse reaction, generating NADPH in the cytosol: In more detail, this reaction involves the oxidation of isocitrate to oxalosuccinate, with NAD(P) + as the electron acceptor, followed by the decarboxylation of oxalosuccinate to form a-ketoglutarate [58].”
Shaldam, M. A., El-Hamaky, A. A., Khattab, N. A., Hefny, S. M., Nafie, M. S., Eldehna, W. M., & Tawfik, H. O. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104797
Attwa, M. W., Abdelhameed, A. S., Alrabiah, H. K., & Kadi, A. A. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70331
Jiang, L., Li, M., Li, Z., Liu, Q., & Li, Y. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71180
BindingDB (2013) · UC San Diego · doi:10.7270/q2x92cf7
Metadata
- Authors
- Reitman, Z. J., & Yan, H.
- Affiliations
- Duke University (US)
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-31
- Volume
- 102
- Issue
- 13
- Pages
- 932-941
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC2897878
- OpenAlex
- W2124951199
- Cited by
- 562
- References
- 88
- Citations by year
- 2026: 22 · 2025: 41 · 2024: 20 · 2023: 33 · 2022: 31 · 2021: 44 · 2020: 40 · 2019: 43 · 2018: 40 · 2017: 36 · 2016: 31 · 2015: 34 · 2014: 28 · 2013: 34 · 2012: 38
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Cancer Institute (R01CA118822, R01CA140316)
- National Institute of General Medical Sciences (T32GM007171)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Keywords
- IDH1, IDH2, IDH1 mutation, IDH2 mutation, cancer metabolism, glioma, acute myeloid leukemia, D-2-hydroxyglutarate, oxidative stress, lipogenesis, oxygen sensing, anticancer agents
- MeSH terms
- Animals, Hypoxia, Arginine, Brain Neoplasms, Codon, Glioblastoma, Glucose, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, NADP, Neoplasms, Oligodendroglioma, Oncogenes, Signal Transduction, Up-Regulation, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
